Switch for VEGF-mediated angiogenesis identified


Munster – German and UK researchers have identified the Jagged1 protein as an on-switch for angiogenesis. A binary decision, determining the fate of a stem cell located on the inner wall of veins and arteries to differentiate into a bloodvessel cell, is made when the Jagged1 protein activates the transmembrane receptor protein Notch on neighbouring endothelial cells. In doing so, the ligand acts as a transducer in the Notch Signal Pathway (NSP), making cells succeptible to Vascular Endothelial Growth Factor (VEGF). VEGF then promotes the growth of new blood vessels. If Notch is not activated by Jagged1, VEGF does not have this effect on the stem cell. This is a mechanism which is used to control the process of bifurcation.
NSP regulates cell-cell communication, mediating cellular differentiation and tissue specific development in eukaryotes. Deregulation causes developmental defects in the networking and branching of blood vessels, which can lead to a disrupted flow of oxygen and nutrients to surrounding tissues. The scientists would like to induce vascularisation to counteract defects that can lead to different pathological indications, such as heart attack or cancer.
'For the first time, we now understand how these individual components work together,' commented Professor Ralf Adams of the Max Planck Institute for Molecular Biomedicine in Germany. 'In experiments on mice, we want to learn how to actively control the growth of blood vessels.' Ultimately, medicines could one day be used to do the same in people, he added.
Since NSP plays an important role in the development, growth and healing of many different types of tissues and organs though, the next step will be to investigate the possible dangers of manipulating Notch.



Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...



Leverkusen - A short statement from the European Medicines Agency (EMA) and a big step for the German biotech Biofrontera. The agency issued a favourable opinion on Biofrontera's marketing approval application for its drug for...



Leverkusen/San Francisco - Bayer HealthCare and Onyx Pharmaceuticals will not to court over Nevaxar. The two companies reached an agreement related to regorafenib, a late-stage oncology compound. Regorafenib is an oral...



Ingelheim/Ridgefield –Boehringer Ingelheim’s COPD treatment Combivent Respimat has been approved by the U.S. Food and Drug Administration (FDA) for the US market. The new, propellant-free inhaler product for the beta adrenergic...



Rostock – German researchers say overexpression of one of the 49 transport proteins that shuttle substances over the blood-brain barrier could be the key to treating Alzheimer’s disease. In mice, the group headed by Jens Pahnke...



Rehovot/Monheim – Bayer Crop Science may be a step closer to introducing desirable traits in wheat. In the collaboration with Israeli Evogene Ltd. the German company has reached a milestone. Utilising Evogene‘s proprietary...



Willich – Brasilian biopolymer producer Braskem and German bioplastics compounding specialist FKuR GmbH, have signed a compounding agreement for green polyethylene. The tailor-made product will be a first in Europe, according...



Leverkusen - It was a black Tuesday for Bayer. After rumours were leaked out that the FDA has doubts over the German pharmaceutical company's potential blockbuster Xarelto, the shares temporarily dropped as much as 17 percent....



Bad Homburg - German VC firm Creathor venture announced the first closing of its Creathor Venture Fund III. Now, the company is poised to mete out €51million of fresh capital to start-ups. Life science companies will be among the...

Displaying results 21 to 30 out of 454

< Previous 21-30 Next >

© 2007-2015 BIOCOM


Product of the week



All Events

Stock list

All quotes


  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%


  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%


  • DBV Technologies (F)52.75 EUR16.9%
  • Allergy Therapeutics (UK)23.50 GBP15.3%


  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.68 EUR-28.8%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%


  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%


  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 03.07.2015

Current issue

All issues